{
    "clinical_study": {
        "@rank": "62037", 
        "acronym": "SEAL PM", 
        "arm_group": {
            "arm_group_label": "Angio-Seal VIP Vascular Closure"
        }, 
        "brief_summary": {
            "textblock": "To characterize the clinical outcomes of Angio-Seal VIP with SJM collagen through the\n      collection of device/procedure-related major vascular complications and time to hemostasis."
        }, 
        "brief_title": "Post-Market Study of the St. Jude Medical Angio-Seal\u2122 VIP Vascular Closure Device", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Vascular Closure", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient requires closure of femoral artery puncture resulting from arterial access\n             procedure.\n\n          -  Patient is \u226518 years of age.\n\n          -  Patient is willing to provide written informed consent prior to study device use.\n\n          -  Patient is willing and able to adhere to data collection and follow-up requirements.\n\n        Exclusion Criteria:\n\n          -  Patient is participating in another clinical trial which has the potential to impact\n             hemostasis.\n\n          -  Patient has an active groin infection or systemic infection.\n\n          -  Patient has undergone a vascular access procedure within the past 90 days.\n\n          -  Patient has been previously enrolled in the study.  (For patients undergoing multiple\n             interventions within a timeframe of 90 days, only the initial procedure may\n             constitute a study enrollment.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients that will be included in the study will be indicated for the procedure according\n        to the Instructions for Use. Physicians should carefully select patients based on the IFU\n        including a consideration of all warnings and precautions."
            }
        }, 
        "enrollment": {
            "#text": "235", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01858636", 
            "org_study_id": "CL06818"
        }, 
        "intervention": {
            "arm_group_label": "Angio-Seal VIP Vascular Closure", 
            "description": "These devices are used for the vascular closure procedure", 
            "intervention_name": "Angio-Seal VIP 6F and 8F devices", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bad Nauheim", 
                        "country": "Germany"
                    }, 
                    "name": "Kerckhoff-Klinik GmbH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Institut f\u00fcr Diagnostiche und Interventionelle Radiologie"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Homburg", 
                        "country": "Germany"
                    }, 
                    "name": "Univ. des Saarlandes"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany"
                    }, 
                    "name": "Herzzentrum Leipzig GMBH"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Breda", 
                        "country": "Netherlands"
                    }, 
                    "name": "Amphia Ziekenhuis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands"
                    }, 
                    "name": "Medisch Spectrum Twente"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Netherlands"
            ]
        }, 
        "number_of_groups": "1", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "Germany: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Major vascular complications include:\nAccess Site Complications:\nHematoma >10 cm in size\nMajor bleeding requiring transfusion of \u22652 units of blood\nPain requiring extended or new hospitalization, or percutaneous or surgical intervention\nInfection requiring extended or new hospitalization or treatment with IV antibiotics\nA/V Fistula requiring medical intervention (percutaneous or surgical)\nPseudoaneurysm requiring medical intervention (percutaneous or surgical)\nLower Limb Ischemia requiring surgical or medical intervention or resulting in permanent injury/impairment\nRetroperitoneal hemorrhage requiring intervention (percutaneous or surgical)", 
                "measure": "The proportion of subjects experiencing a device or procedure related major vascular complication", 
                "safety_issue": "Yes", 
                "time_frame": "30 days post procedure"
            }, 
            {
                "measure": "The proportion of subjects that achieve hemostasis within 5 minutes of device deployment.", 
                "safety_issue": "Yes", 
                "time_frame": "within 5 minutes of device deployment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01858636"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}